[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: WT1-Targeted Immunotherapy

June 2018 | 52 pages | ID: C38D52304B7EN
La Merie Publishing

US$ 354.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis: WT1-Targeted Immunotherapy

This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

Wilms‘ tumor 1 (WT1) oncoprotein is a zinc finger transcription factor whose expression in normal adult tissue is rare but is overexpressed in leukemias of multiple lineages and a wide range of solid tumors. WT1 expression is a biomarker and a prognostic indicator. RNA interference knockdown studies of WT1 suggest that it has oncogenic potential and it appears to be expressed in leukemia stem cell populations. A National Institutes of Health–convened panel ranked WT1 as a top cancer target for immunotherapy. WT1 is a nuclear protein, inaccessible to classical antibody therapy, but vaccine approaches are under way to generate WT1-specific cytotoxic T cell (CTL) responses that recognize peptides presented on the cell surface by MHC class I molecules. Engineering autologous T-cells with a WT1-specific T-cell receptor (TCR) is another approach currently pursued.

The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies targeting Wilms Tumor 1 (WT1). In addition, the report lists company- and institution-specific R&D pipelines of WT1-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) WT1-TARGETED IMMUNOTHERAPY

Selective WT1-Targeted Vaccines
WT1-Specific, Multi-Target Vaccines
WT1-Selective Adoptive Cell Therapy
WT1-Specific, Multi-Target Adoptive Cell Therapy
WT1-Targeted Antibodies

2) CORPORATE & INSTITUTIONAL WT1 IMMUNOTHERAPY R&D PIPELINES


More Publications